Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes

International Journal of Cardiology

Volumn 156, Issue 2, 2012, Pages 199-202

  Chao, Tze Fan ^a,b   Leu, Hsin Bang ^a,b   Huang, Chin Chou ^a,b   Chen, Jaw Wen ^a,b   Chan, Wan Leong ^a,b   Lin, Shing Jong ^a,b   Chen, Shih Ann ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Atrial fibrillation; Diabetes mellitus; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; TAIWAN;

ADULT; AGED; ATRIAL FIBRILLATION; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 84858275950     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.081     Document Type: Article

References (33)

1. P.A. Wolf, J.B. Mitchell, C.S. Baker, W.B. Kannel, and R.B. D'Agostino Impact of atrial fibrillation on mortality, stroke, and medical costs Arch Intern Med 158 1998 229 234 (Pubitemid 28123885)
2. S.S. Chugh, J.L. Blackshear, W.K. Shen, S.C. Hammill, and B.J. Gersh Epidemiology and natural history of atrial fibrillation: clinical implications J Am Coll Cardiol 37 2001 371 378
3. W.B. Kannel, P.A. Wolf, E.J. Benjamin, and D. Levy Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates Am J Cardiol 82 1998 2N 9N (Pubitemid 28507114)
4. A.D. Krahn, J. Manfreda, R.B. Tate, F.A. Mathewson, and T.E. Cuddy The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study Am J Med 98 1995 476 484
5. S.M. Vaziri, M.G. Larson, E.J. Benjamin, and D. Levy Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study Circulation 89 1994 724 730 (Pubitemid 24056200)
6. M.R. Movahed, M. Hashemzadeh, and M.M. Jamal Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease Int J Cardiol 105 2005 315 318 (Pubitemid 41605083)
7. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D'Agostino, A.J. Belanger, and P.A. Wolf Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 271 1994 840 844
8. T.A. Aksnes, R.E. Schmieder, S.E. Kjeldsen, S. Ghani, T.A. Hua, and S. Julius Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial) Am J Cardiol 101 2008 634 638 (Pubitemid 351625088)
9. C.J. Boos, R.A. Anderson, and G.Y. Lip Is atrial fibrillation an inflammatory disorder? Eur Heart J 27 2006 136 149 (Pubitemid 43069029)
10. T. Liu, G. Li, L. Li, and P. Korantzopoulos Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis J Am Coll Cardiol 49 2007 1642 1648 (Pubitemid 46551628)
11. P. Korantzopoulos, T.M. Kolettis, D. Galaris, and J.A. Goudevenos The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation Int J Cardiol 115 2007 135 143 (Pubitemid 46136515)
12. S. Giannini, M. Serio, and A. Galli Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity J Endocrinol Invest 27 2004 982 991 (Pubitemid 40124199)
13. J. Plutzky The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis Am J Cardiol 92 2003 34J 41J
14. R. Qayyum, and J. Adomaityte Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels Am J Cardiol 97 2006 655 658 (Pubitemid 43255034)
15. R. Da Ros, R. Assaloni, and A. Ceriello The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance Diabet Med 21 2004 1249 1252 (Pubitemid 39472383)
16. T.T. Issac, H. Dokainish, and N.M. Lakkis Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data J Am Coll Cardiol 50 2007 2021 2028 (Pubitemid 350087568)
17. J.L. Anderson, C.A. Allen Maycock, and D.L. Lappe Frequency of elevation of C-reactive protein in atrial fibrillation Am J Cardiol 94 2004 1255 1259 (Pubitemid 39469943)
18. M.K. Chung, D.O. Martin, and D. Sprecher C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation Circulation 104 2001 2886 2891 (Pubitemid 33139098)
19. Y.J. Lin, H.M. Tsao, and S.L. Chang Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation Am J Cardiol 105 2010 495 501
20. X. Chen, Z. Bing, and J. He Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation Clin Cardiol 32 2009 337 345
21. Y.H. Kim, D.S. Lim, and J.H. Lee Gene expression profiling of oxidative stress on atrial fibrillation in humans Exp Mol Med 35 2003 336 349 (Pubitemid 37474465)
22. S.C. Dudley Jr., N.E. Hoch, and L.A. McCann Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases Circulation 112 2005 1266 1273 (Pubitemid 41268651)
23. T. Liu, P. Korantzopoulos, G. Li, and J. Li The potential role of thiazolidinediones in atrial fibrillation Int J Cardiol 128 2008 129 130 (Pubitemid 351905768)
24. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82 (Pubitemid 28079218)
25. D. Yu, S.J. Murdoch, and S.J. Parikh Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy Diab Vasc Dis Res 3 2006 189 196 (Pubitemid 44902486)
26. J. Hwang, D.J. Kleinhenz, B. Lassegue, K.K. Griendling, S. Dikalov, and C.M. Hart Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production Am J Physiol Cell Physiol 288 2005 C899 C905
27. I. Villegas, A.R. Martin, W. Toma, and C.A. de la Lastra Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation Eur J Pharmacol 505 2004 195 203 (Pubitemid 39535692)
28. M. Shimano, Y. Tsuji, and Y. Inden Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure Heart Rhythm 5 2008 451 459
29. M. Fu, J. Zhang, and X. Zhu Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3 J Biol Chem 276 2001 45888 45894
30. Y.H. Yeh, C.T. Kuo, and T.H. Chan Transforming growth factor-{beta} and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes Cardiovasc Res 91 2011 62 70
31. M.W. Anglade, J. Kluger, C.M. White, J. Aberle, and C.I. Coleman Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study Curr Med Res Opin 23 2007 2849 2855 (Pubitemid 350146423)
32. P. Korantzopoulos, S. Kokkoris, E. Kountouris, I. Protopsaltis, K. Siogas, and A. Melidonis Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy Int J Cardiol 125 2008 e51 e53
33. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2